Federal contractor · TUCSON, AZ

NUVOX PHARMA, L.L.C.

No contract obligations recorded for NUVOX PHARMA, L.L.C. in FY2026. Since FY2023: $356.4K. It also received $1.1M in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
WHNYG96UDLJ8
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 749.4KFY2023
  2. -393KFY2025

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for NUVOX PHARMA, L.L.C. in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

NUVOX PHARMA, L.L.C. received $1.1M in federal assistance in FY2026, on 4 actions (0 new awards), −13% vs FY2025. Its largest program was 93.394 · Cancer Detection and Diagnosis Research ($1.1M).

Assistance · FY2026
$1.1M
New awards
0
Actions
4
Since FY2021
$5.1M

Assistance by fiscal year

  1. 478.1KFY2021
  2. 1.2MFY2022
  3. 793.9KFY2023
  4. 299.2KFY2024
  5. 1.2MFY2025
  6. 1.1MFY2026

By type

  1. Grants$1.1M100%

Top programs

  1. 93.394 · Cancer Detection and Diagnosis Research$1.1M100%

Awarding agencies

  1. National Institutes of Health$1.1M100%
    Department of Health and Human Services

Largest awards

  1. LIQUID BIOPSY IN GLIOBLASTOMA TREATED WITH CHEMORADIATION AND AN OXYGEN THERAPEUTIC - HYPOTHESIS AND SPECIFIC AIMS OUTCOMES FOR PATIENTS…$2M
    93.394 · Cancer Detection and Diagnosis Research· National Institutes of Health· Project grant· Sep 23, 2025 – Aug 27, 2026· R44CA298498
  2. DODECAFLUOROPENTANE EMULSION (DDFPE), NANO2? AS CEREBROPROTECTANT IN ISCHEMIC STROKE - ABSTRACT / PROJECT SUMMARY STROKE AFFECTS MORE THAN…$900.6K
    93.853 · Extramural Research Programs in the Neurosciences and Neurological Disorders· National Institutes of Health· Cooperative agreement· Apr 7, 2023 – Aug 14, 2026· U44NS130589
  3. NANO2 ENHANCES IMMUNOTHERAPY IN TRIPLE NEGATIVE BREAST CANCERS.$900.4K
    12.420 · Military Medical Research and Development· Defense Health Agency· Project grant· Jul 26, 2022 – Aug 5, 2026· W81XWH2210639

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.